Samuel Backenroth, Chief Financial Officer at Ohr Pharmaceutical Inc (OHRP), bought 2,468 shares at $2.71 ($7K) on 2016-06-20, disclosed to the SEC on 2016-06-21.
Open-market purchase of $7k OHRP by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.71 | 200 | $542 | 7.7% |
| 2 | $2.84 | 1,800 | $5K | 73.1% |
| 3 | $2.87 | 450 | $1K | 18.5% |
| 4 | $2.88 | 8 | $23 | 0.3% |
| 5 | $2.89 | 10 | $29 | 0.4% |
| Total | $2.84 avg | 2,468 |
| $7K |
| 100% |
| Filing → |
| OHRP | BUY | 2016-05-24 | $8K | — | Filing → |
| OHRP | BUY | 2015-02-10 | $10K | — | Filing → |